Russia invaded Ukraine on 24 of February 2022. Stand with Ukraine and support us in a fight for freedom and democracy in Europe.  Stand with Ukraine!  Join us

Discover the Best Clinics and Costs for Kidney cancer treatment in Italy 2024

Content meets the Bookimed Editorial Policy and is medically reviewed by
Fahad Mawlood - General practitioner. Winner of 4 scientific awards. Served in Western Asia. Former Team Leader of a medical team supporting Arabic-speaking patients. Now responsible for data processing and medical content accuracy.
Discover the Best Clinics and Costs for Kidney cancer treatment in Italy 2024

Kidney cancer Treatment Overview in Italy

Bookimed fees - $0
Doctors - 2
Clinics - 1

What's the Cost of Kidney cancer Diagnostic and Treatment Procedures in Italy? Find Out Now

updated 4/30/2024
The average price for Kidney cancer diagnostic and treatment in Italy is $303, the minimum price is $232, and the maximum price is $375.
Request the price
United States of America Turkey Mexico
Laparoscopic nephrectomy from $16000 from $12000 -
CyberKnife from $23000 from $4750 -
Gamma Knife -from $5500 -
Proton-beam therapy ---
Nephrectomy from $14000 from $3550 -
Da Vinci Robotic System from $11000 from $2500 -
NanoKnife -from $3000 -
Radiation therapy for colorectal cancer -from $3250 -
Chemotherapy for breast cancer from $10000 from $300 -
Immunotherapy for kidney cancer -from $10000 -
Cryotherapy for kidney cancer ---
Nephrectomy with Da Vinci Robot ---
Chemotherapy for kidney cancer ---
Radiation therapy for kidney cancer -from $3250 -
PET/CT from $1300 from $700 -
Biopsy from $3800 from $2000 from $430
Extended analysis of blood from $250 from $3219 -
CT (computer tomography) from $350 from $1 from $292
Consultation with an oncologist -from $325 -
Сomplex oncology diagnostic -from $7000 -
Histopathology revision -from $300 -
CT of the chest -from $92 -
Complex diagnostics of kidney ---
Complex diagnostics of kidney cancer ---
CT of the paranasal sinuses -from $33 -
The total cost is calculated individually. It may range depending on your medical issue, doctor's qualification, procedure complexity and related complications (if they occur). You’ll get the exact price for a plastic surgery procedure after a consultation with a doctor.
Below average
Above average
According to 1 clinic presented in the ranking
Discover the Best Kidney cancer Clinics in Italy: 1 Verified Option and Prices
Check the hospital ranking based on requests and 0 reviews to pick the right Kidney cancer clinic for you.
Italy, Rome
92% patients recommend

Read more details Hide details

Located in Oblia (Sardinia), Mater Olbia Hospital is an international center of excellence, created by combining the skills and the respective experiences of Qatar Foundation Endowment and Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome.

The Mater Olbia Hospital is a preferred destination for patients from around the world, in search of top-level expertise, cutting-edge technology and modern and luxurious premises.

Submit a free request
Ask us any question you might have
We’ll respond in 5 minutes

Get a Medical Assessment for Kidney cancer Treatment in Italy: Select Your Expert from 2 Experienced Doctors

Italy, Milan
Francesco Montorsi
Urological surgeon
32 years of experience
San Raffaele
Prof. Montorsi is one of the top Italian experts in urology and andrology. Holds numerous scientific awards. Directs the Urological Research Institute (URI) in Italy. Recognized among the most influential researchers of the past decade. Specialty Professor Montorsi provides treatments of bladder, prostate, kidney cancer with the help of minimally invasive surgery and robotic techniques. Has provided over 8,000 urology & andrology surgeries. Has developed his method of vein patching to correct the occlusive vein dysfunction. Work experience Since 2013 — Scientific Director of the San Raffaele Scientific Institute (Italy) Director of the Urological Research Institute (URI) at the Urology Department of the Vita-Salute San Raffaele University of Milan Education   1987 — The Medical Faculty at the University of Milan — Degree in medicine and surgery 1992 — The Medical Faculty at the University of Milan — Specialty in urology 2017 — The Royal College of Surgeons of England — Honorary fellowship. Awards 1998 — The Crystal Matula Award from the European Association of Urology as the Best European Urologist Under 40 2016 — The Commander of the Order of Merit of the Italian Republic 2018 — The Hugh Hampton Young Award from the American Urological Association for outstanding contributions to the science of urology & urologic oncology (Dr. Montorsi is the first non-American who has received this award) 2019 — The Frans Debruyne Lifetime Achievement Award from the European Association of Urology for outstanding contribution to the Association development. Scientific activity Professor Montorsi has written over 1,000 papers. The Web Science Group has included the doctor in the list of the most influential researchers of the past decade. Teaching activity Since 2012 — Director of the Urology School — The Vita-Salute San Raffaele University (Italy) 2008-2012 — Professor of Urology — The Vita-Salute San Raffaele University (Italy) 2002-2008 — Associate Professor of Urology — The Vita-Salute San Raffaele University (Italy). Membership in organizations The Association of Academic European Urologists (AAEU) The American Association of Genito-Urinary Surgeons The American Urological Association The Endourological Society The European Association of Urology The European Society for Sexual Medicine (ESSM) The Italian Society of Andrology (SIA) The Italian Society of Urology.
Italy, Milan
Armando Santoro
Clinical oncologist
44 years of experience
HUMANITAS RESEARCH HOSPITAL
Professor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities. He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977.  In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa.  Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University.  Current Positions:  .Since 1997, he is the Director of the Department of Medical Oncology and Haematology, at Istituto Clinico Humanitas, Milan. Also, he is Member of the Ethics Committee of Istituto Clinico Humanitas and Director of Clinical Research in the same Institute since 2007. - Since 2008, he is Member of the Planning Committee, Ministry of Work and of Health and Social Politics, Rome, Italy. - Since October 2008, Professor Santoro is Counsellor of the Board of Directors of the Fondazione Humanitas for Research of Rozzano, Italy. - Since November 2008, he is Expert Member of the National Centre for the Prevention and Control of Disease, Ministry of Work and of Health and Social Politics (Rome, Italy). - Since February 2009, he is National Representative preparatory actions for the "European Partnership for Action against Cancer" Ministry of Work and of Health and Social Politics (Rome, Italy). - Since February 2009, Professor Santoro is member of National Italian Committee on the Research Network in Oncology, Ministry of Work and of Health and Social Politics (Rome, Italy). - Since May 2009, he is Coordinator of the Oesophageal-Stomach Cancer Group Coordinator of the Liver and Biliary Tree Cancer Group, Regional Oncology Commission – Lombardy Oncology Network.   In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009).      Publications: santoro%a - Search Results - PubMed (nih.gov) 

FAQ about Kidney cancer Treatment in Italy

Kidney cancer

Kidney cancer (kidney carcinoma) is a malignant tumor that occurs in organ cells. Male patients aged from 50 to 70 are subjects at higher risk of kidney cancer development.

Tumor affects one, much less often - both kidneys. 50% patients have renal cell cancer. In all other cases, malignant tumor develops in ureter, kidney pelvis. Kidney sarcoma is diagnosed in less than 10% patients.

Tumor cells develop in retroperitoneal space that шы poorly palpable. Early stages of the disease are asymptomatic. Tumor is often detected during scheduled ultrasound when it already has large size.

Typical symptoms of kidney cancer:

blood in urine (hematuria);

severe lumbar pain;

abdominal induration palpable during examination;

increased temperature and blood pressure;

podedema.

Kidney cancer diagnostics

Kidney ultrasound is the most available method but it does not provide an accurate diagnosis. Therefore, kidney cancer diagnostics should include a set of procedures:

  • Ultrasound of abdominal cavity and urinary system – defines changing of the shape, size of kidney and tumor location;
  • expanded blood laboratory tests (including oncomarkers) and urinalysis;
  • computed tomography (CT) with contrast – “golden standard” of kidney cancer diagnostics. It shows precise location, size of the tumor, depth of its growth into an organ and stages the diseases. CT also enables determining of metastases;
  • MRI is rarely applied for kidney carcinoma. It is used when CT is contraindicated;
  • biopsy – standard examination for cancer diagnosis. For kidney cancer biopsy is not always informative. Therefore, it is performed only upon doctor’s recommendation;
  • renal angiography, X-ray study and bone scanning – X-rays examinations aiming at determine metastases in lungs, bone tissue. It is carried out when CT with contrast is absent.

Kidney cancer stages: treatment and survival rate

Stage 1

At the early stage of kidney cancer a tumor sizes not more than 7 cm. It is located in the kidney and does not spreads into surrounding organs, tissues. Stage 1 is poorly diagnosed and has no specific symptoms.

Stage 1 kidney cancer treatment

Survival rate. Rehabilitation

  • Tumor removal with kidney preservation.
  • Radical nephrectomy – complete kidney removal. It can be performed in three ways: abdominal operation, laparoscopic or Da Vinci robotic-assisted surgery.

81 — 90 %

After the treatment patients return to normal life with some restrictions concerning their diet and physical activities.

Examination of nephrologist/urologist is required every 6 months during 2 years after the surgery, than - once per year.

Stage 2

Stage 2 kidney cancer spreads into adrenals or pararenal fat. The tumor sizes over 7 cm but is located only in renal area. There is no metastases.

Stage 2 kidney cancer treatment

Survival rate. Rehabilitation

Removal of the kidney with adherent fatty tissue, sometimes with adrenals, adjusting vessels, lymph nodes.

74 %

После лечения пациент возвращается к повседневной жизни, соблюдая диету, режим.

20 % patients have a risk of metastasizing therefore they have to undergo diagnostics each 3 - 6 months, than — every year during 5 years.

Stage 3

At stage 3 kidney cancer tumor starts to spread into lymph nodes. There is no distant metastases. Cancer can spread into renal vein or vena cava thus causing complications.

Stage 3 kidney cancer treatment

Survival rate. Rehabilitation

Removal of the kidney with adherent fatty tissue, sometimes with adrenals, adjusting vessels, lymph nodes.

40 – 65 %

Regular examination – every 3 months during 3 years after the surgery. Than – one time per year.

Stage 4

Stage 4 kidney cancer is difficult to treat. It has multiple distant metastases, tumor expands quickly and aggressively.

Stage 4 kidney cancer treatment

Survival rate. Rehabilitation

  • Radical nephrectomy + surgical metastasectomy – removal of kidney and tumors in other organs.
  • Target and/or immune therapy
  • Chemotherapy

10 % – 14%

Treatment significantly prolongs patient’s life, increases its quality. Palliative treatment is applied for pains relieve.

This page may feature information relating to various medical conditions, treatments, and healthcare services available in different countries. Please be advised that the content is provided for informational purposes only and should not be construed as medical advice or guidance. Please consult with your doctor or a qualified medical professional before starting or changing medical treatment.

Bookimed editorial policy

Bookimed, a leading global medical tourism platform, is committed to helping clients looking for Kidney cancer treatment by offering expert assistance and trustworthy medical solutions for every situation. Smart automatic ranking system is used to compose transparent clinic listings, meticulously maintained by a data scientist using AI for accuracy. The platform guarantees authenticity by publishing reviews from real patients after their treatments. Bookimed offers comprehensive medical solutions, with updates from clinics to ensure trustworthiness. The content about Kidney cancer treatment, crafted by experienced medical authors and reviewed by specialists, adheres to Bookimed"s Editorial Guidelines, reflecting the platform"s commitment to delivering high-quality and clear health information. For more details or inquiries, feel free to contact us at marketing@bookimed.com or learn more about us and our mission here.

Kidney cancer Bookimed Medical Advisory Board expert

Doctor Yesim Yildirim is an oncologist certified by the European Society of Medical Oncology (ESMO). Affiliated with numerous hospitals in the United States and Turkey, including the University of Maryland Medical Center, Johns Hopkins Hospital and Memorial Sisli Hospital. She has over 20 years of experience and has a special interest in preventive medicine, diabetes, and hypertension. Holds an MBA in Healthcare Management and shares her expertise with Bookimed from 2022.

The Medical Advisory Board expert is a verified credible medical professional with solid theoretical background and practical experience in the field. The expert provides support related to medical content accuracy for medical writers and performs educational workshops to Bookimed coordinators serving patient requests.

The medical content creation under the expert’s control follows rigorous and well-established procedure to be informative, trustworthy, and transparent and making Bookimed.com a credible source of evidence-based health information.